Marco Quarta
Co-founder & Chief Scientific Officer Rubedo LifeSciences
Seminars
Wednesday 28th January 2026
A Phase 1 Basket Trial: Randomized, Double-Blind, Vehicle-Controlled Study of a First-in-Class Selective Senolytic GPX4 Modulator (RLS-1496) in Patients with Chronic Inflammatory Skin Diseases & in Aged Skin
1:30 pm
- Targeting Senescent Cell Heterogeneity: Senescent cells are diverse, and distinct molecular pathways drive different subtypes. In skin aging and multiple chronic inflammatory skin diseases, specific senescent cell populations act as key pathological drivers
- Mechanism of Action: RLS-1496, a first-in-class GPX4 modulator discovered through the Alembic AI-enabled drug discovery platform, selectively induces ferroptosis in pathogenic senescent cell subtypes implicated in dermatological tissue aging and disease progression
- Clinical Translation: RLS-1496 has advanced into a Phase 1 basket trial, a randomized, double-blind, vehicle controlled study, evaluating safety, tolerability, and early efficacy signals in both chronic inflammatory skin diseases and aged skin
